Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MOGAT2 | Q3SYC2 | 7/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23658699 | 0.81 | MOGAT2 (0.31) | MOGAT2 | |
| SCHEMBL23648684 | 0.79 | — | — | |
| SCHEMBL23648243 | 0.66 | MOGAT2 (0.33) | MOGAT2 | |
| SCHEMBL23647755 | 0.63 | MOGAT2 (0.38) | MOGAT2 | |
| SCHEMBL23648062 | 0.61 | PDK2 (0.42) | MOGAT2 | |
| SCHEMBL8881506 | 0.61 | MOGAT2 (0.46) | MOGAT2 | |
| SCHEMBL3595402 | 0.61 | BRD4 (0.37) | — | |
| SCHEMBL23648075 | 0.60 | ALDH1A1 (0.39) | MOGAT2 | |
| SCHEMBL23648081 | 0.60 | AR (0.46) | MOGAT2 | |
| SCHEMBL23648098 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4090661-B1 | QUINOXALINE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR | GRUENENTHAL GMBH (DE) | 2025-03-12 | — | — | EP | disclosed |
| US-20220372041-A1 | QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2022-11-24 | — | — | US | disclosed |
| EP-4090661-A1 | QUINOXALINE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR | Grünenthal GmbH (DE) | 2022-11-23 | — | — | EP | disclosed |
| WO-2021144440-A1 | QUINOXALINE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR | Grünenthal GmbH (DE) | 2021-07-22 | — | — | WO | disclosed |
| WO-2021144440-A1 | QUINOXALINE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR | Grünenthal GmbH (DE) | 2021-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220372041-A1 | QUINOXALINE DERIVATIVES | NR3C1, NR3C2, GRK5 | MOGAT2 3478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.